|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:alsoKnownAs
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
gptkb:Vaxzevria
gptkb:AZD1222
gptkb:Covishield
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:India
gptkb:United_Kingdom
many other countries
30 December 2020
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
2020 introductions
AstraZeneca products
Viral vector vaccines
|
|
gptkbp:contains
|
SARS-CoV-2 spike protein gene
|
|
gptkbp:developedBy
|
gptkb:University_of_Oxford
gptkb:AstraZeneca
gptkb:Serum_Institute_of_India
|
|
gptkbp:dosingSchedule
|
two doses
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
about 70%
|
|
gptkbp:emergencyServices
|
gptkb:India
gptkb:World_Health_Organization
gptkb:UK_Medicines_and_Healthcare_products_Regulatory_Agency
gptkb:European_Medicines_Agency
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ChAdOx1-S
|
|
gptkbp:manufacturer
|
gptkb:SK_Bioscience
gptkb:AstraZeneca
gptkb:Serum_Institute_of_India
gptkb:R-Pharm
gptkb:Fiocruz
|
|
gptkbp:notRecommendedFor
|
people with history of severe allergic reaction to vaccine ingredients
|
|
gptkbp:rareAdverseEvent
|
thrombosis with thrombocytopenia syndrome
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
injection site pain
|
|
gptkbp:storage
|
2–8 °C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vectorFor
|
gptkb:chimpanzee_adenovirus
|
|
gptkbp:WHOEmergencyUseListing
|
15 February 2021
|
|
gptkbp:bfsParent
|
gptkb:Astra_In-Ze
|
|
gptkbp:bfsLayer
|
7
|